Eisai Co., Ltd. (ESALF)
OTCMKTS
· Delayed Price · Currency is USD
35.98
-2.52 (-6.55%)
Sep 25, 2024, 9:30 AM EDT
Eisai Revenue
Eisai had revenue of 189.03B JPY in the quarter ending June 30, 2024, a decrease of -4.01%. This brings the company's revenue in the last twelve months to 733.85B, down -3.07% year-over-year. In the fiscal year ending March 31, 2024, Eisai had annual revenue of 741.75B, down -0.36%.
Revenue (ttm)
733.85B JPY
Revenue Growth
-3.07%
P/S Ratio
2.41
Revenue / Employee
66.31M JPY
Employees
11,067
Market Cap
10.85B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | 695.62B | 52.79B | 8.21% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.69B |
Ryman Healthcare Limited | 411.39M |
Verano Holdings Corp. | 920.97M |
Medexus Pharmaceuticals Inc. | 108.78M |
Eisai News
- 12 days ago - Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer - Seeking Alpha
- 12 days ago - KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma - Benzinga
- 17 days ago - Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges - Benzinga
- 18 days ago - Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment - CNBC
- 5 weeks ago - Biogen, Eisai new Alzheimer’s drug considered too costly in Britain - Seeking Alpha
- 5 weeks ago - Biogen/Eisai’s Alzheimer's drug wins marketing authorization in Great Britain - Seeking Alpha
- 5 weeks ago - UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug - Reuters
- 5 weeks ago - Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED - Seeking Alpha